Thursday, August 27, 2026

HBM's 3x Wafer Cost Keeps Global AI Memory Prices Elevated Through 2027

Three companies — South Korea's SK hynix and Samsung, and US-based Micron — control virtually all high-bandwidth memory supply while global AI demand is forecast to grow 35x by 2028. DRAM contract prices are projected to rise 58–63% in Q2 2026 alone, with Gartner forecasting a 125% full-year increase. A structural manufacturing constraint, not market timing, is driving the shortage.

LM Salvado
LM Salvado

May 12, 2026

HBM's 3x Wafer Cost Keeps Global AI Memory Prices Elevated Through 2027
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Three manufacturers — South Korea's SK hynix, Samsung, and US-based Micron — control virtually all HBM supply. Each gigabyte of HBM requires three times the wafer capacity of standard DRAM.1 That physics-driven constraint is why no production ramp resolves the shortage quickly.

DRAM contract prices are forecast to rise 58–63% in Q2 2026 alone.1 Gartner projects a 125% full-year DRAM price increase for 2026.2 Both SK hynix and Samsung warn the shortage will persist through at least end of 2027.1

Demand is accelerating from every direction simultaneously. Counterpoint Research forecasts HBM demand from custom AI processors will grow 35x between 2024 and 2028.3 US hyperscalers, Chinese cloud giants, and European AI infrastructure builders are all competing for the same constrained wafer output.

HBM stacks multiple DRAM dies vertically using through-silicon vias (TSVs), delivering the wide memory bandwidth that large language models require. That stacking process demands more wafer area per unit of storage — a manufacturing reality that limits gigabyte output even as fab capacity expands.

Micron's stock has surged 162% year-to-date in 2026.1 Markets are pricing in a sustained premium, not a temporary spike. The company's Singapore facility is on a production ramp timeline targeting H2 2028.1 Until new capacity comes online across all three suppliers, supply growth remains structurally capped.

For AI infrastructure builders worldwide, the bottleneck is direct. HBM bandwidth determines model serving throughput. Constrained HBM supply means constrained AI inference capacity — regardless of GPU production volumes anywhere in the world.

The mismatch between 35x projected demand growth and supply expansion measured in single-digit percentages annually defines the structural case for elevated pricing through 2027.3 Wafer area is finite. HBM's manufacturing requirements are not shrinking. Until Micron's Singapore lines and expanded Korean fab capacity reach production scale, the constraint holds globally.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Network, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com